A meta-analysis published today in AJP in Advance reports the maximum effective dose for 20 antipsyc...

The Food and Drug Administration (FDA) has approved Latuda (lurasidone HCl) for the treatment of dep...

Lurasidone appears to be well tolerated and effective at reducing depressive symptoms in children an...

Despite the fact that early nonresponse to antipsychotic therapy in patients with schizophrenia is k...

Once daily treatment with lurasidone for six weeks decreased depressive and manic symptoms in patien...

An eight-week, randomized, controlled study published today in AJP in Advance has found that a 1.5 m...

In July, lurasidone—a dopamine receptor 2 (D2) blocker originally approved to treat schizophrenia—wa...

The U.S. Food and Drug Administration (FDA) has approved new indications for the atypical antipsycho...